Skip to main content
Clinical Trials/NCT05429671
NCT05429671
Completed
Phase 3

Drug Elution Profile and Minimum Inhibitory Concentration of Antibiotic-loaded Cement After Primary Total Knee Arthroplasty

Rothman Institute Orthopaedics1 site in 1 country50 target enrollmentJune 20, 2022

Overview

Phase
Phase 3
Intervention
total knee arthroplasty
Conditions
Total Knee Arthoplasty
Sponsor
Rothman Institute Orthopaedics
Enrollment
50
Locations
1
Primary Endpoint
Antibiotic concentration
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

This study will provide us with clear information about the postoperative concentration of antibiotic reached in synovial fluid, thereby helping surgeons to determine if concentration could potentially prevent the growth and regrowth of common infecting microorganisms (based on their MIC and MBEC). There is a need to define the actual benefit of antibiotic-loaded bone cement, because the addition of antibiotic can reduce its mechanical strength. Moreover, if sub-therapeutic antibiotic levels are achieved, this could facilitate the emergence of resistant bacterial strains. Amidst the transition towards value-based care, our research will enable surgeons to decide whether antibiotic-loaded cement is truly cost-effective in the prevention of PJI.

Registry
clinicaltrials.gov
Start Date
June 20, 2022
End Date
November 30, 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • All participants undergoing cemented primary total knee arthroplasty (TKA) who are 18 years or older.

Exclusion Criteria

  • Withdrawal of informed consent,
  • allergy to any of the study medications or to bone cement,
  • use of antibiotics within 4 weeks before collecting the samples (not including perioperative antimicrobial prophylaxis),
  • high risk of infection,
  • history of peri-articular injections for multimodal pain management.

Arms & Interventions

Group A (Control-negative group)

include participants undergoing total knee arthroplasty with Stryker Surgical Simplex P cement containing no antibiotic

Intervention: total knee arthroplasty

Group B (tobramycin group)

includes participants undergoing total knee arthroplasty with Stryker Surgical Simplex P cement with tobramycin antibiotic.

Intervention: total knee arthroplasty

Group B (tobramycin group)

includes participants undergoing total knee arthroplasty with Stryker Surgical Simplex P cement with tobramycin antibiotic.

Intervention: Tobramycin

Group C (gentamicin group)

Include participants undergoing total knee arthroplasty with Huraeus Palacos R+G cement containing gentamicin antibiotic.

Intervention: total knee arthroplasty

Group C (gentamicin group)

Include participants undergoing total knee arthroplasty with Huraeus Palacos R+G cement containing gentamicin antibiotic.

Intervention: Gentamicin

Group D (Control-positive group)

Include participants undergoing the first of a two-stage exchange arthroplasty for confirmed infection, using an antibiotic-loaded cement spacer. These patients will have a spacer implant made of vancomycin and tobramycin antibiotics using Huraeus Palacos non-antibiotic loaded cement

Intervention: total knee arthroplasty

Group D (Control-positive group)

Include participants undergoing the first of a two-stage exchange arthroplasty for confirmed infection, using an antibiotic-loaded cement spacer. These patients will have a spacer implant made of vancomycin and tobramycin antibiotics using Huraeus Palacos non-antibiotic loaded cement

Intervention: Antibiotic cement spacer

Outcomes

Primary Outcomes

Antibiotic concentration

Time Frame: 24 hours

To determine antibiotic levels, synovial fluid (joint fluid) would be taken after surgery to measure the concentration of antibiotic in the joint fluid

Study Sites (1)

Loading locations...

Similar Trials